BlackRock’s Minerva Neurosciences NERV Stock Holding History

BlackRock’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.76M	Buy	624,857 +552,188	+760%	+$3.17M	﹤0.01%	3938
2025 Q4	$292K	Hold	72,669	–	–	﹤0.01%	4621
2025 Q3	$153K	Hold	72,669	–	–	﹤0.01%	4735
2025 Q2	$125K	Hold	72,669	–	–	﹤0.01%	4786
2025 Q1	$124K	Hold	72,669	–	–	﹤0.01%	4719
2024 Q4	$161K	Hold	72,669	–	–	﹤0.01%	4663
2024 Q3	$194K	Hold	72,669	–	–	﹤0.01%	4529
2024 Q2	$232K	Hold	72,669	–	–	﹤0.01%	4517
2024 Q1	$187K	Hold	72,669	–	–	﹤0.01%	4597
2023 Q4	$447K	Hold	72,669	–	–	﹤0.01%	4448
2023 Q3	$501K	Sell	72,669 -6,162	-8%	-$55.2K	﹤0.01%	4424
2023 Q2	$721K	Hold	78,831	–	–	﹤0.01%	4381
2023 Q1	$126K	Hold	78,831	–	–	﹤0.01%	4903
2022 Q4	$125K	Buy	78,831 +745	+1%	+$3.22K	﹤0.01%	4974
2022 Q3	$721K	Buy	78,086 +27,612	+55%	+$164K	﹤0.01%	4600
2022 Q2	$166K	Sell	50,474 -12,261	-20%	-$50.1K	﹤0.01%	5086
2022 Q1	$417K	Sell	62,735 -572	-0.9%	-$3.51K	﹤0.01%	4920
2021 Q4	$406K	Buy	63,307 +2,261	+4%	+$21.3K	﹤0.01%	4932
2021 Q3	$850K	Buy	61,046 +10,238	+20%	+$154K	﹤0.01%	4601
2021 Q2	$943K	Sell	50,808 -240,863	-83%	-$5.18M	﹤0.01%	4533
2021 Q1	$6.81M	Buy	291,671 +15,272	+6%	+$382K	﹤0.01%	3795
2020 Q4	$5.17M	Buy	276,399 +13,801	+5%	+$348K	﹤0.01%	3698
2020 Q3	$6.68M	Sell	262,598 -13,792	-5%	-$373K	﹤0.01%	3449
2020 Q2	$7.98M	Buy	276,390 +15,331	+6%	+$899K	﹤0.01%	3310
2020 Q1	$12.6M	Sell	261,059 -2,834	-1%	-$171K	﹤0.01%	2874
2019 Q4	$15M	Sell	263,893 -36,817	-12%	-$1.62M	﹤0.01%	3039
2019 Q3	$18.6M	Buy	300,710 +2,334	+0.8%	+$132K	﹤0.01%	2857
2019 Q2	$13.4M	Sell	298,376 -847	-0.3%	-$42.4K	﹤0.01%	3067
2019 Q1	$18.8M	Sell	299,223 -7,890	-3%	-$474K	﹤0.01%	2772
2018 Q4	$16.6M	Buy	307,113 +1,072	+0.4%	+$78.5K	﹤0.01%	2823
2018 Q3	$30.7M	Buy	306,041 +33,328	+12%	+$2.5M	﹤0.01%	2642
2018 Q2	$18M	Buy	272,713 +27,426	+11%	+$1.67M	﹤0.01%	2921
2018 Q1	$12.3M	Sell	245,287 -7,060	-3%	-$339K	﹤0.01%	3028
2017 Q4	$12.2M	Sell	252,347 -9,117	-3%	-$452K	﹤0.01%	3043
2017 Q3	$15.9M	Buy	261,464 +34,291	+15%	+$1.97M	﹤0.01%	2914
2017 Q2	$16.1M	Buy	227,173 +37,382	+20%	+$2.42M	﹤0.01%	2900
2017 Q1	$12.3M	Buy	189,791 +189,673	+160,740%	+$14.7M	﹤0.01%	3015
2016 Q4	$11K	Hold	118	–	–	﹤0.01%	3372
2016 Q3	$13K	Buy	118 +40	+51%	+$3.88K	﹤0.01%	3360
2016 Q2	$6K	Buy	+78	New	+$4.96K	﹤0.01%	3488

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

BlackRock's NERV Position: Q1 2026 in Review

BlackRock increased its Minerva Neurosciences (NERV) stake by 760% in Q1 2026, buying an estimated $3.17M and bringing the position to 624,857 shares worth $3.76M. The position accounts for ﹤0.01% of the portfolio, ranked #3938.

BlackRock first reported a position in NERV in Q2 2016 and has held it in 40 quarters since. The position peaked at $30.7M in Q3 2018. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

BlackRock held 624,857 shares of Minerva Neurosciences worth $3.76M as of Q1 2026.
BlackRock bought 552,188 Minerva Neurosciences shares in Q1 2026, an estimated $3.17M.
Minerva Neurosciences made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3938 holding.
BlackRock first reported a position in Minerva Neurosciences in Q2 2016 and has held it in 40 quarters since.
BlackRock's Minerva Neurosciences position peaked at $30.7M in Q3 2018.
47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.